CN115671146A - Plant-derived extracellular vesicles, uses thereof and products comprising same - Google Patents

Plant-derived extracellular vesicles, uses thereof and products comprising same Download PDF

Info

Publication number
CN115671146A
CN115671146A CN202211281683.3A CN202211281683A CN115671146A CN 115671146 A CN115671146 A CN 115671146A CN 202211281683 A CN202211281683 A CN 202211281683A CN 115671146 A CN115671146 A CN 115671146A
Authority
CN
China
Prior art keywords
cancer
cells
extracellular vesicles
cell
plant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211281683.3A
Other languages
Chinese (zh)
Other versions
CN115671146B (en
Inventor
刘冠宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Fumai Biotechnology Co ltd
Shanghai Shengtejia Health Technology Development Co ltd
Original Assignee
Shanghai Fumai Biotechnology Co ltd
Shanghai Shengtejia Health Technology Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fumai Biotechnology Co ltd, Shanghai Shengtejia Health Technology Development Co ltd filed Critical Shanghai Fumai Biotechnology Co ltd
Priority to CN202211281683.3A priority Critical patent/CN115671146B/en
Publication of CN115671146A publication Critical patent/CN115671146A/en
Application granted granted Critical
Publication of CN115671146B publication Critical patent/CN115671146B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02Algae
    • A61K36/03Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a plant-derived extracellular vesicle, use thereof and a product comprising the same. The extracellular vesicles are capable of acting as NK cell activators to stimulate NK cells to release proteins, such as perforin and/or granzyme, thereby exerting cytotoxicity. The plant-derived extracellular vesicles of the invention overcome the problem of reduced capability of NK cells to attack cancer cells, enhance the capability of NK cells to attack cancer cells, and improve the treatment effect of NK cells on cancer.

Description

Plant-derived extracellular vesicles, uses thereof and products comprising same
The invention is a divisional application of original application with application date of 2021, 03/26, application number of 202110327946.9, entitled "extracellular vesicles of plant origin, uses thereof, and products containing the same".
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a plant-derived extracellular vesicle, application thereof and a product containing the same.
Background
On the surface of natural killer cells (NK), receptor molecules (KIR) that inhibit NK cell activation are expressed. Since Major Histocompatibility Complex (MHC) molecules can bind to KIRs, cells expressing MHC molecules can signal and thus are not killed by NK cells. Normal cells always express MHC molecules to indicate themselves, so NK cells do not kill normal cells expressing MHC molecules. If "cancer cells" that do not express MHC proteins are present, NK cells will kill these cancer cells.
NK cell therapy aims to apply this property to cancer treatment. However, experience has shown that it is very difficult to treat solid tumors with NK cells. One of the reasons is that the normal culture method of NK cells does not activate it well or many cells of the immune system are depleted due to side effects of anticancer drug therapy due to autologous cell transplantation. This is believed to be the reason why the ability of NK cells to attack cancer cells themselves is greatly reduced. In addition, in order to increase the therapeutic effect of NK cells, NK cell proliferating agents such as IL-2 (interleukin-2) or IL-15 (interleukin-2) are now used in vitro or in vivo to promote the proliferation of NK cells, increase the number of NK cells, and maintain the long-term growth of NK cells. However, the NK cells are aged during the proliferation process, and thus the therapeutic effect of the application of the NK cells is poor.
Therefore, there is a need to find an agent that can effectively activate NK cells to treat cancer.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a novel application of plant-derived Extracellular Vesicles (EV) and patient NK cells for in-vitro co-culture, wherein the plant-derived extracellular vesicles can activate the release of NK cell perforin and granzyme, enhance the attack capacity of NK cells on cancer cells, and overcome the problem of the reduction of the capacity of the NK cells for attacking the cancer cells.
(II) technical scheme
In one aspect, the present invention provides an NK cell activator comprising plant-derived extracellular vesicles.
In another aspect, the present invention provides a composition comprising the NK cell activator of the present invention, and an NK cell proliferation-expanding agent.
In another aspect, the present invention provides the use of the NK cell activator of the present invention or the composition of the present invention for the preparation of a medicament for the treatment of cancer.
In another aspect, the present invention provides a pharmaceutical composition for treating cancer, comprising the NK cell activator of the present invention or the composition of the present invention, and a pharmaceutically acceptable carrier.
In another aspect, the present invention provides a method for treating cancer, comprising administering to a subject an NK cell activator, composition or pharmaceutical composition of the present invention.
(III) advantageous effects
Compared with the prior art, the invention has the following beneficial effects:
the cytoplasmic granules of NK cells contain proteins such as perforin and granzyme, which play a central role in the cytotoxic activity of killing cancer cells. Perforin is released by the injured cells and pierces the cell membrane of the cancer cells, thereby allowing the entry of granzymes and related molecules. Granzymes are serine proteases that induce apoptosis in the cytoplasm of target cells, such as cancer cells. The present inventors have found that plant-derived extracellular vesicles can be used to stimulate NK cells to release large amounts of proteins (e.g. perforin and granzyme) that are the major functional factors of cytotoxicity of the NK cells. The plant-derived extracellular vesicles provided by the invention overcome the problem of reduced capability of NK cells to attack cancer cells, enhance the capability of NK cells to attack cancer cells, and enhance the treatment effect of NK cells on cancers.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 shows increase in expression amount of granzyme by NK cells;
FIG. 2 shows that the expression level of FAS-L by NK cells is increased;
FIG. 3 shows that the expression amount of TNF-. Alpha.of NK cells was increased;
FIG. 4 shows that the IL-2 secretion amount of NK cells was increased.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Plant-derived extracellular vesicles
The plant-derived extracellular vesicles provided by the present invention can increase the amount of proteins (e.g., perforin and granzyme) released by NK cells. These proteins are the major functional factors of NK cell cytotoxicity and are the weapon of NK cells to attack cancer cells.
The plant-derived extracellular vesicles provided by the present invention can also increase the expression level of TNF family molecules (e.g., FAS-L, TRAIL, TNF- α, and TWEAK) on the surface of NK cells. TNF family molecules bind to the corresponding receptors expressed on target cells, thereby inducing apoptosis.
The plant-derived extracellular vesicles provided by the present invention can also increase the amount of interleukin-2 (IL-2) secreted by NK cells. IL-2 can activate a variety of immune cells, including B cells, NK cells, LAK cells, monocytes, macrophages, and oligodendrocytes.
The plant-derived extracellular vesicles provided by the invention enhance the killing effect of NK cells on cancer cells through one or more of the above effects.
The extracellular vesicles described in the present invention are derived from seaweed. In a specific embodiment, the extracellular vesicles are derived from Phaeophyceae (Phaeophyceae) plants. In a more specific embodiment, the extracellular vesicles are derived from plants of the genus nephelium (Ectocarpus). In a more specific embodiment, the extracellular vesicles are derived from hydroclouds or sea clouds (Nemacystus decipiens). In a more specific embodiment, the extracellular vesicles are derived from adherent algae commonly known as "mozuku". It is a brown algae, which has been eaten worldwide since ancient times, and is filamentous, about 1 to 3.5 mm thick and 25 to 40 cm long. Characterised by the surface of the fronds being adherent and of viscous composition
Fucoidan (Fucoidan) is about 5 to 8 times as high as that of undaria pinnatifida and kelp. In one embodiment of the invention, the extracellular vesicles are extracted from fucoidan extracted from seaweed.
In one embodiment of the invention, extracellular vesicles are prepared by:
-extracting fucoidan from the seaweed,
-extracting extracellular vesicles from fucoidan by ultracentrifugation.
In one embodiment of the present invention, extracellular vesicles may be prepared by:
extracting and refining low molecular power fucosan from Phaeophyceae plant
Centrifugation of the supernatant after precipitation (not taking the precipitate),
the supernatant (with the green pellet, which is removed) is taken by ultracentrifugation,
-obtaining extracellular vesicles of plant origin in the supernatant.
In one embodiment of the invention, extracellular vesicles are prepared by:
-extracting fucoidan from the seaweed,
-dissolving the fucoidan in PBS,
centrifugation at 2,000 Xg for 10 minutes at 4 ℃,
-taking the supernatant and centrifuging at 35,000rpm for 70 minutes at 4 ℃,
washing the pellet with PBS,
-centrifuging again at 35,000rpm for 70 minutes at 4 ℃,
the supernatant was discarded, and the PBS liquid containing the suspended matter at the bottom was centrifuged at 10,000x g at 4 ℃ for 10 minutes to remove the green precipitate, to obtain a supernatant containing extracellular vesicles.
In the present invention, the numbers referred to in the preparation steps include the range of the value. + -. 10%. For example, 10 minutes includes a range of 9 minutes to 11 minutes. Yet another example 35,000rpm includes the range of 31,500rpm to 38,500rpm.
In a preferred embodiment, the molecular weight of the fucan is less than or equal to about 500 daltons, such as less than or equal to 400Dal, less than or equal to 450Dal, less than or equal to 460Dal, less than or equal to 470Dal, less than or equal to 480Dal, less than or equal to 490Dal, less than or equal to 495Dal, less than or equal to 500Dal, less than or equal to 505Dal, or less than or equal to 510Dal.
Extraction of low molecular (less than about 500 molecular weight) power fucoidan from seaweeds is known in the art, for example, as disclosed in professor kyu-tanaka-juju 23526. Alternatively, commercially available power fucoidans (e.g., JAN: 4580123711060) may be used. Thus, in a specific embodiment, the extracellular vesicles of plant origin are extracted from fucoidan.
In one embodiment of the invention, the extracellular vesicles are exosomes (exosomes).
NK cell proliferation-expanding agent
The plant-derived extracellular vesicles may be used alone or may be used together with an NK cell proliferation-expanding agent to activate NK cells. The NK cell proliferation-expanding agent includes IL-2 and/or IL-15.
Thus, in a specific embodiment, the present invention provides a pharmaceutical composition comprising the NK cell activating agent of the present invention, and an NK cell proliferation-expanding agent. In a more specific embodiment, the pharmaceutical composition includes an NK cell activator and IL-2. In another more specific embodiment, the pharmaceutical composition comprises an NK cell activator and IL-15. In another more specific embodiment, the pharmaceutical composition includes an NK cell activator, IL-2 and IL-15.
Cancer treatment
The plant-derived extracellular vesicles provided by the present invention can be used for treating cancer.
In a particular embodiment, the cancer may be a hematological tumor or a solid tumor.
In a more specific embodiment, the solid tumor can be ovarian cancer, melanoma, breast cancer, gastric cancer, colorectal cancer, relapsed refractory neuroblastoma, merkel cell carcinoma, rectal cancer, lung cancer, prostate cancer, pancreatic cancer, bladder cancer, cervical cancer, cholangiocarcinoma, gastrarcoma, glioma, osteosarcoma, or brain cancer.
In a more specific embodiment, the hematological tumor can be a leukemia, myeloma, or lymphoma.
In a more specific embodiment, the leukemia can be Acute Lymphocytic Leukemia (ALL), acute Myelogenous Leukemia (AML), chronic Lymphocytic Leukemia (CLL), chronic Myelogenous Leukemia (CML), hairy cell leukemia, T-cell prolymphocytic leukemia, or large granular lymphocytic leukemia.
In a more specific embodiment, the myeloma can be an asymptomatic myeloma, a smoldering myeloma (SMM), a Multiple Myeloma (MM), or a light chain myeloma.
In a more specific embodiment, the lymphoma can be a non-hodgkin lymphoma of hodgkin's lymphoma, T cell lymphoma, and B cell lymphoma.
Pharmaceutical composition
The present invention provides a pharmaceutical composition comprising the NK cell activator of the present invention, and a pharmaceutically acceptable carrier.
The invention also provides a pharmaceutical composition, which comprises the NK cell activating agent and the NK cell proliferation and amplification agent, and a pharmaceutically acceptable carrier.
In a specific embodiment, the pharmaceutically acceptable carrier may be any one of or a combination of at least two of diluents, excipients, fillers, binders, wetting agents, disintegrants, emulsifiers, cosolvents, solubilizers, osmotic pressure regulators, surfactants, pH regulators, antioxidants, bacteriostats, and buffering agents.
Method of treatment
The present invention provides a method of treating cancer comprising administering to a subject an NK cell activator of the present invention.
In a specific embodiment, the present invention provides a method of treating cancer comprising: administering to the patient a therapeutically effective amount of plant-derived extracellular vesicles. The plant-derived extracellular vesicles activate NK cells in vivo, promote the NK cells to secrete perforin, granzyme, TNF family molecules and IL-2 to express or release, and enhance the killing capacity of the NK cells on cancer cells.
The administration route includes intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration or transdermal administration.
Combination therapy
The NK cell activating agent of the present invention may also be used in combination with other anticancer drugs. Thus, any of the above pharmaceutical compositions may also comprise other anti-cancer drugs.
The pharmaceutical composition can be in the form of injection, tablet, capsule, granule, suspension, emulsion, solution, lyophilized powder, aerosol or microsphere.
In a specific embodiment, examples of other anticancer drugs include cisplatin, thalidomide, oxaliplatin, carboplatin, mitoxantrone, doxorubicin, sunitinib, imatinib, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, carmustine, semustine, lomustine, streptozotocin, methotrexate, fluorouracil, floxuridine, gemcitabine, mercaptopurine, thioguanine, pentostatin, cladribine, fludarabine, vinblastine, vincristine, paclitaxel, docetaxel, etoposide, teniposide, topotecan, irinotecan, daunorubicin, doxorubicin, bleomycin, mitomycin, noroxydianrubicin, epirubicin, buserelin, prednisone, hydroxyprogesterone caproate, medroxyprogesterone acetate, diethylstilbestrol, ethisterone, tamoxifene, tamoxifen, anastrozole, flutolterodine, tolterodine, tolnaftate, and leuprolide.
In a specific embodiment, the pharmaceutical composition of the present invention and the anticancer drug may be administered simultaneously or sequentially.
Other routes of anticancer drug administration include intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, oral administration, sublingual administration, nasal administration, or transdermal administration.
Examples
Example 1: preparation of plant-derived extracellular vesicles
1. 1 pack of power fucoidan (JAN: 4580123711060) was transferred to a 50mL test tube.
2. It was fully homogenized using a 20 ml syringe (no needle) 5 accesses.
3. 1g aliquots were added to 50mL PBS, respectively.
4. The mixture was stirred with a stirrer for 1 hour.
5. And standing for 15 minutes.
6. 45mL of the supernatant was centrifuged at 2,000 Xg at 4 ℃ for 10 minutes.
7. The supernatant was taken (no pellet was taken).
8. Pass through a 0.22um filter.
9. Centrifuge at 35,000rpm for 70 minutes at 4 ℃.
10. The pellet was washed with PBS.
11. The mixture was centrifuged again at 35,000rpm at 4 ℃ for 70 minutes.
12. The supernatant was discarded and the bottom PBS solution containing the suspension was transferred to a 1.5mL tube.
13. Centrifugation was carried out at 10,000x g for 10 minutes at 4 ℃ and (with a green precipitate, this was removed).
14. The supernatant was transferred to a new tube to obtain plant-derived extracellular vesicles.
Example 2: function of plant-derived extracellular vesicles in enhancing content of NK cell granzyme
First, the amount of granzyme B of human NK cells (Lonza, poietics. TM. Human NK cells; product code: 2W-501) to which no extracellular vesicles were added was quantified and set to 1.0. Then, the human NK cells were incubated with the plant-derived extracellular vesicles prepared in example 1 at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then a relative value of the amount of granzyme B was calculated. A control group was additionally provided. Human NK cells were incubated with DC cell (dendritic) -derived extracellular vesicles at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then a relative value of the amount of granzyme B was calculated. Methods for the preparation of DC cell derived extracellular vesicles are known in the art. The amount of Granzyme B was quantified by ELISA using the Granzyme B ELISA development kit (human alkaline phosphatase) (product code: 3485-1A-6, cosmo Bio Inc.) following the protocol of the attached specification. The results of the experiment are plotted in figure 1.
As shown in fig. 1, the expression of granzyme B in NK cells increased more than 8-fold after the addition of plant-derived extracellular vesicles. While the expression of granzyme B in NK cells increased more than 5-fold upon addition of DC cell-derived extracellular vesicles (data not shown).
Example 3: effect of plant-derived extracellular vesicles on enhancing expression level of FAS-L in NK cells
FAS-L is a TNF family molecule expressed on the surface of NK cells that induces cell death by binding to the FAS-L receptor expressed on target cells (e.g., cancer cells). Therefore, it was quantitatively analyzed whether plant-derived extracellular vesicles increased the expression level of FAS-L in human NK cells. For the quantification of FAS-L, human soluble FasL ligand was quantitatively determined colorimetrically using an ELISA kit (FasL, soluble ELISA kit; cosmo Bio product code: ALX-850-246-KI 01). The method follows the attached description.
First, the amount of FAS-L in human NK cells to which no extracellular vesicles were added was quantified using a kit, and this value was set to 1.0. Then, human NK cells were incubated with the plant-derived extracellular vesicles prepared in example 1 at a concentration of 100 extracellular vesicles/human NK cells for 72 hours, and then a relative value of the amount of FasL was calculated. A control group was additionally provided. Human NK cells were incubated with DC cell-derived extracellular vesicles at a concentration of 100 extracellular vesicles/human NK cells for 72 hours, and then relative values of the amount of FasL were calculated. The results of the experiment are plotted in figure 2.
As shown in FIG. 2, the expression of FAS-L in NK cells was increased 3-fold after the addition of plant-derived extracellular vesicles. After addition of DC cell-derived extracellular vesicles, expression of FAS-L was increased 1.9-fold in NK cells (data not shown).
Example 4: effect of plant-derived extracellular vesicles on enhancing TNF-alpha expression level in NK cells
Similar to FAS-L, TNF- α, a TNF family molecule, binds to TNF- α receptors expressed on target cells (e.g., cancer cells), thereby inducing cell death. Therefore, it was quantitatively analyzed whether the extracellular vesicles increased the expression level of TNF-. Alpha.in human NK cells. TNF-. Alpha.was quantified by the ELISA kit (human TNF-. Alpha.assay ELISA kit; cosmo Bio product code: KE 00068) by the sandwich method on a 96-well plate coated with a capture antibody. The method in practice follows the attached instructions.
First, the amount of TNF- α in human NK cells without extracellular vesicles was quantified with the kit, and set to 1.0. Then, the human NK cells were incubated with the plant-derived extracellular vesicles prepared in example 1 at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then a relative value of the amount of TNF- α was calculated. A control group was additionally provided. Human NK cells were incubated with DC cell-derived extracellular vesicles at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then relative values of TNF- α amounts were calculated. The results of the experiment are plotted in fig. 3.
As shown in fig. 3, TNF- α expression in NK cells increased 3.4 fold after addition of plant-derived extracellular vesicles. TNF- α expression in NK cells increased 2.3 fold after addition of DC cell-derived extracellular vesicles (data not shown).
Example 5: plant-derived extracellular vesicles enhance IL-2 secretion in NK cells
Interleukin 2 (IL-2) is the major immunoregulatory cytokine produced by T cells in response to antigen stimulation and mitogen activation. Signals emitted through the IL-2 receptor pathway are important for T cell proliferation and provide other necessary functions for normal immune responses. IL-2 signals through the IL-2 receptor complex. IL-2 also activates a variety of immune cells, including B cells, NK cells, LAK cells, monocytes, macrophages and oligodendrocytes. IL-2 is a major cytokine widely used in therapeutic prescription. Therefore, it was quantitatively analyzed whether plant-derived extracellular vesicles increased the IL-2 expression level of human NK cells. For the quantification of IL-2, human soluble IL-2 was quantified by sandwich method using ELISA kit (human IL-2 assay ELISA kit; cosmoBio product code: KE 00017) on a 96-well plate coated with capture antibody by sandwich method. The method follows the attached description.
First, the amount of IL-2 in human NK cells to which no extracellular vesicles were added was quantified with a kit and set to 1.0. Then, human NK cells were incubated with the plant-derived extracellular vesicles prepared in example 1 at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then a relative value of the amount of IL-2 was calculated. A control group was additionally provided. Human NK cells were incubated with DC cell-derived extracellular vesicles at a concentration of 100 extracellular vesicles/human NK cells for 48 hours, and then relative values of the amount of IL-2 were calculated. The results of the experiment are plotted in fig. 4.
As shown in fig. 4, the amount of IL-2 secreted by NK cells increased 2.9-fold upon addition of plant-derived extracellular vesicles. After addition, the amount of IL-2 secreted by NK cells increased 1.8-fold (data not shown).
Discussion of the preferred embodiments
The plant-derived extracellular vesicles of the present invention can significantly increase the release amount of proteins (including perforin and granzyme) of NK cells and the expression amount of TNF family molecules and IL-2, compared to the control group to which no extracellular vesicles were added and the control group to which DC cell-derived extracellular vesicles were added. Therefore, the NK cells are effectively activated, so that the problem that the capability of the NK cells for attacking the cancer cells is reduced in the prior art is solved, the capability of the NK cells for attacking the cancer cells is enhanced, the treatment effect of the NK cells on cancers is enhanced, and the cancer cells can be specifically inhibited.
The above examples are only intended to illustrate the technical solution of the present invention, and not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims (10)

1. An NK cell activator, characterized in that the NK cell activator comprises plant-derived extracellular vesicles.
2. The NK cell activator according to claim 1, wherein the extracellular vesicle is an exosome.
3. The NK cell activator according to claim 1 or 2, wherein the plant is a seaweed;
preferably, the seaweed is a plant of the class phaeophyceae;
further preferably, the phaeophyceae plant is a hydrocloud or a marine cloud.
4. The NK cell activator according to any one of claims 1 to 3, wherein the extracellular vesicles are extracted from fucoidan extracted from seaweed;
preferably, the extracellular vesicles are prepared by:
-extracting fucoidan from the seaweed,
-extracting extracellular vesicles from fucoidan by ultracentrifugation;
further preferably, the extracellular vesicles are prepared by:
-extracting fucoidan from the seaweed,
-dissolving fucoidan in PBS,
centrifugation at 2,000 Xg at 4 ℃ for 10 minutes,
-taking the supernatant, centrifuging it at 35,000rpm for 70 minutes at 4 ℃,
washing the pellet with PBS,
-centrifuging again at 35,000rpm for 70 minutes at 4 ℃,
the supernatant was discarded, and the PBS liquid containing the suspended matter at the bottom was centrifuged at 10,000x g at 4 ℃ for 10 minutes to remove the green precipitate, and the supernatant containing extracellular vesicles was obtained.
5. The NK cell activator according to claim 4, characterized in that the molecular weight of the fucan is less than or equal to 500 daltons.
6. A composition comprising the NK cell activating agent according to any one of claims 1 to 5, and an NK cell proliferation-expanding agent,
preferably, the NK cell proliferation expansion agent includes IL-2 and/or IL-15.
7. Use of the NK cell activator of any one of claims 1 to 5 or the composition of claim 6 for the preparation of a medicament for the treatment of cancer.
8. The use according to claim 7, wherein the cancer is a hematological tumor and a solid tumor;
preferably, the solid tumor is ovarian cancer, melanoma, breast cancer, gastric cancer, colorectal cancer, relapsed refractory neuroblastoma, merkel cell carcinoma, rectal cancer, lung cancer, prostate cancer, pancreatic cancer, bladder cancer, cervical cancer, cholangiocarcinoma, gastrarcoma, glioma, osteosarcoma, or brain cancer;
preferably, the hematological tumor is a leukemia, myeloma or lymphoma,
further preferably, the leukemia is acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, T-cell prolymphocytic leukemia or large granular lymphocytic leukemia;
further preferably, the myeloma is asymptomatic myeloma, smoldering myeloma, multiple myeloma or light chain myeloma;
further preferably, the lymphoma is a non-hodgkin's lymphoma of hodgkin's lymphoma, T-cell lymphoma and B-cell lymphoma.
9. A pharmaceutical composition for treating cancer, comprising the NK cell activator of any one of claims 1 to 5 or the composition of claim 6, and a pharmaceutically acceptable carrier.
10. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is in the form of injection, tablet, capsule, granule, suspension, emulsion, solution, lyophilized powder, aerosol, or microsphere;
preferably, the pharmaceutical composition further comprises other anti-cancer drugs; further preferably, the additional anticancer drug is selected from the group consisting of cisplatin, thalidomide, oxaliplatin, carboplatin, mitoxantrone, doxorubicin, sunitinib, imatinib, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, carmustine, semustine, lomustine, streptozotocin, methotrexate, fluorouracil, floxuridine, gemcitabine, mercaptopurine, thioguanine, pentostatin, cladribine, fludarabine, vinblastine, vincristine, paclitaxel, docetaxel, etoposide, teniposide, topotecan, irinotecan, daunorubicin, doxorubicin, bleomycin, mitomycin, demethoxydaunorubicin, epirubicin, buserelin, prednisone, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, tamoxifene, anastrozole, flutrexone, testosterone, bicalutamide, tiprex, leuprolide, and leuprolide.
CN202211281683.3A 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, use thereof and products comprising same Active CN115671146B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211281683.3A CN115671146B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, use thereof and products comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110327946.9A CN113209140B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, uses thereof and products comprising same
CN202211281683.3A CN115671146B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, use thereof and products comprising same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202110327946.9A Division CN113209140B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, uses thereof and products comprising same

Publications (2)

Publication Number Publication Date
CN115671146A true CN115671146A (en) 2023-02-03
CN115671146B CN115671146B (en) 2023-09-19

Family

ID=77084259

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110327946.9A Active CN113209140B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, uses thereof and products comprising same
CN202211281683.3A Active CN115671146B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, use thereof and products comprising same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110327946.9A Active CN113209140B (en) 2021-03-26 2021-03-26 Plant-derived extracellular vesicles, uses thereof and products comprising same

Country Status (1)

Country Link
CN (2) CN113209140B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115161254A (en) * 2022-03-11 2022-10-11 中国农业大学 Method for improving yield of extracellular vesicles of lactic acid bacteria
CN115161215A (en) * 2022-03-11 2022-10-11 中国农业大学 Fermentation method of bifidobacterium and application thereof
WO2023242605A1 (en) 2022-06-14 2023-12-21 Támogatott Kutatócsoportok Irodája Extracellular vesicles for use in therapy
CN115671394A (en) * 2022-11-23 2023-02-03 国纳之星(上海)纳米科技发展有限公司 Preparation of injectable calcium phosphate bone cement loaded with plant exosomes, and product and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110448696A (en) * 2019-08-30 2019-11-15 河南科技大学 Preparation method and application based on salt algae excretion body targeted delivery of drugs carrier
US20200230196A1 (en) * 2017-02-01 2020-07-23 Yeditepe Universitesi Product containing plant derived exosomes
CN111567798A (en) * 2020-06-08 2020-08-25 浙江大学 Construction method of targeted intestinal slow-release functional factor exosome based on brown algae

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5147218B2 (en) * 2006-11-13 2013-02-20 ハイドロックス株式会社 Seaweed-derived immunostimulant and anti-inflammatory agent
KR101794114B1 (en) * 2016-08-02 2017-11-06 인제대학교 산학협력단 Composition for preventing or treating cancer comprising the extract of Sargassum thunbergii
CN111543637B (en) * 2020-06-08 2022-07-22 浙江大学 Construction method of targeting liver slow-release functional factor exosome based on brown algae

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200230196A1 (en) * 2017-02-01 2020-07-23 Yeditepe Universitesi Product containing plant derived exosomes
CN110448696A (en) * 2019-08-30 2019-11-15 河南科技大学 Preparation method and application based on salt algae excretion body targeted delivery of drugs carrier
CN111567798A (en) * 2020-06-08 2020-08-25 浙江大学 Construction method of targeted intestinal slow-release functional factor exosome based on brown algae

Also Published As

Publication number Publication date
CN113209140B (en) 2022-11-22
CN113209140A (en) 2021-08-06
CN115671146B (en) 2023-09-19

Similar Documents

Publication Publication Date Title
CN113209140B (en) Plant-derived extracellular vesicles, uses thereof and products comprising same
CN113462645B (en) Composition comprising NK cells and exosomes of plant origin, uses thereof and products comprising same
Poggi et al. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive
Saleh et al. Immunomodulatory properties of Coriolus versicolor: the role of polysaccharopeptide
CN108699523B (en) NK cell culture medium addition kit and NK cell culture method using same
Zhang et al. An in vivo anti-tumor effect of eckol from marine brown algae by improving the immune response
Lee et al. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal
KR20090127974A (en) A medium composition for cultivating self activated lymphocyte
KR20090127973A (en) A method for cultivating self activated lymphocyte
Zhang et al. Ecklonia cava fucoidan has potential to stimulate natural killer cells in vivo
Yang et al. Fucoidan-supplemented diet potentiates immune checkpoint blockage by enhancing antitumor immunity
JP2021519087A (en) Use of histone modifiers to reprogram effector T cells
He et al. The immunomodulatory effect of triptolide on mesenchymal stromal cells
An et al. Polysaccharides from Astragalus membranaceus elicit T cell immunity by activation of human peripheral blood dendritic cells
Li et al. CD49a+ CD49b+ NK cells induced by viral infection reflect an activated state of conventional NK cells
Karimi-Shahri et al. Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend
Han et al. Biological Character of RetroNectin Activated Cytokine‐Induced Killer Cells
Joo Altered maturation of dendritic cells by taxol, an anticancer drug
Ghazvinian et al. Contribution of natural killer cells in innate immunity against colorectal cancer
WO2013191664A1 (en) Method of producing cik cells and the cik cells produced by the method thereof and the use for treating cancer cells
CN107073039B (en) Immunotherapy for cancer treatment
KR102633742B1 (en) Natural killer cells having increased anti-cancer activity and immunotherapy uses thereof
JP2023540827A (en) Method for producing highly pure and highly efficient naturally killed cells and their uses
KR20220082138A (en) Compositions comprising Fucoidan from Ecklonia cava as an active ingredient
Demel et al. Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant